Chen Dexiang is the founder of MAXVAX. Latest round: Series B. Backed by China Life Equity Investment, Sherpa Healthcare Partners, GL Ventures.
Chen Dexiang is the Founder and General Manager of MAXVAX, a biotechnology company specializing in the R&D of innovative vaccines and new adjuvants. The company focuses on developing preventive and therapeutic vaccines for infectious diseases, cancer, and allergies, and has established over ten innovative vaccine pipelines, with two currently in the clinical stage. MAXVAX recently completed a Series B funding round, raising nearly RMB 500 million (approximately $74 million).
Full founder directory · Investor directory · Company funding database · Fundraising library